Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
SS-31 vs. Liraglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
- Both have FDA-approved products for defined, product-specific indications.
⇄ Different
Biggest Difference
SS-31 is distinguished by a mitochondrial cardiolipin-binding tetrapeptide with a narrow accelerated approval—not a receptor agonist or a general-purpose energy peptide; Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
SS-31 is distinguished in the current record by a mitochondrial cardiolipin-binding tetrapeptide with a narrow accelerated approval—not a receptor agonist or a general-purpose energy peptide. Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceLiraglutide
SS-31: Mixed human evidence. Liraglutide: Mature human evidence.
Regulatory historyComparable
SS-31: Narrow FDA accelerated approval. Liraglutide: FDA approved for defined product-specific indications.
Mechanistic breadthSS-31
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
SS-31
- Barth syndrome
- Primary mitochondrial myopathy
- Dry age-related macular degeneration
- Heart failure
Liraglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Adolescent obesity
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
SS-31Narrow accelerated approval
FDA accelerated approval as FORZINITY to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. Other uses remain unapproved.
LiraglutideFDA-labeled indications
FDA approved in product-specific daily injection formulations for chronic weight management, type 2 diabetes, and cardiovascular-risk reduction in a defined diabetes population.
Evidence depthEvidence, not a winner
SS-31Mixed controlled trials
A very small Barth program, a negative 218-participant Phase 3 primary-mitochondrial-myopathy trial, negative primary outcomes in Phase 2 heart-failure and dry-AMD trials, and recruiting confirmatory programs.
LiraglutideMature Phase 3 + outcomes
Multiple randomized Phase 3 trials and the 9,340-participant LEADER cardiovascular outcomes trial, with adult and pediatric product-specific evidence.
Weight outcomesEvidence, not a winner
SS-31No dedicated benefit
No controlled human weight-management or body-composition benefit has been established.
LiraglutidePeer-reviewed Phase 3
SCALE reported −8.4 kg mean change at 56 weeks versus −2.8 kg placebo. STEP 8 directly compared liraglutide 3.0 mg with semaglutide 2.4 mg.
Type 2 diabetesEvidence, not a winner
SS-31No approved indication
No FDA-approved diabetes indication or completed controlled diabetes-outcome program was located.
LiraglutideApproved + pediatric trial
Victoza has extensive adult evidence and controlled pediatric evidence beginning at age 10. Product-specific labeled doses differ from weight-management use.
Obstructive sleep apnoeaEvidence, not a winner
SS-31No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome study was located.
LiraglutideControlled study; not approved
A 359-participant trial found a larger reduction in apnea–hypopnea index than placebo, but no U.S. liraglutide OSA indication was identified.
Cardiovascular outcomesEvidence, not a winner
SS-31Negative Phase 2 primary outcome
The 71-participant PROGRESS-HF trial did not improve left-ventricular end-systolic volume or ejection fraction over four weeks. Barth cardiac observations come from a tiny uncontrolled extension.
LiraglutideLEADER + labeled use
LEADER found fewer major cardiovascular events in adults with type 2 diabetes and high cardiovascular risk, supporting a defined Victoza indication.
Administration and handlingEvidence, not a winner
SS-31FORZINITY label only
FORZINITY has product-specific FDA labeling as a ready-to-use once-daily subcutaneous solution. That label does not establish dosing, reconstitution, compatibility, or storage for powdered or unverified SS-31 materials.
LiraglutideDaily product-specific injection
Current approved products are once-daily subcutaneous, ready-to-use solutions. Saxenda and Victoza have different labeled dose ranges, purposes, and instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether the intermediate strength endpoint predicts meaningful functional benefit, plus long-term safety and efficacy outside Barth syndrome.
- Long-term comparative outcomes versus newer weekly incretin therapies and whether narrower research findings become approved uses.
Community Intelligence
Emerging patterns, clearly separated from evidence
SS-31
No community experiences yetBe the first account holder to contribute.
Liraglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.